Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders
Launched by CENTRE HOSPITALIER INTERCOMMUNAL CRETEIL · Jan 11, 2019
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
Ovarian stimulation is an essential prerequisite for any in vitro fertilization attempt (IVF) to optimize the chances of delivery per cycle. These depend in the first place on the age of the patients and secondly on the number of oocytes collected. There is a strong correlation between these two factors, the ovarian reserve diminishing with age. In older patients or patients with decreased reserve, however, the number of oocytes collected remains a prognostic factor for the chances of delivery.
At the present time, there is no validated intervention that would bring a significant interest ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women from 20 to 41 years old
- • CFA \<5 and / or AMH \<1, 2 ng / ml
- • 19 ≤ BMI ≤ 32
- • Supports IVF or ICSI
- • If antecedent IVF / ICSI, number of oocytes collected \<4
- • Attack rank (puncture with transfer) \<3
- • Affiliation to the general social security scheme and benefiting from 100% infertility
- Exclusion Criteria:
- • Confirmed ovarian insufficiency (amenorrhea)
- • FSH\> 20 IU / l or CFA \<1
- • Puncture rank\> 3
- • Azoospermia or cryptozoospermia
- • Against indication to ovarian stimulation
- • Presence of a cyst of indeterminate etiology, ovarian, uterine or mammary carcinoma, hypothalamic or pituitary tumors
- • Hypersensitivity to any of the medicines in the protocol
- • Moderate or severe pathology of renal or hepatic function
- • Evolutionary thromboembolic accidents
About Centre Hospitalier Intercommunal Creteil
Centre Hospitalier Intercommunal Créteil (CHIC) is a leading healthcare institution in the Val-de-Marne department of France, dedicated to delivering high-quality medical care and advancing clinical research. As a prominent clinical trial sponsor, CHIC collaborates with healthcare professionals and academic institutions to facilitate innovative research initiatives aimed at improving patient outcomes. The center is committed to adhering to rigorous ethical standards and regulatory guidelines, ensuring the safety and efficacy of interventions tested within its clinical trials. CHIC’s multidisciplinary approach fosters an environment of collaboration and excellence, positioning it as a key player in the advancement of medical knowledge and therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bruges, , France
Créteil, , France
Marseille, , France
Montpellier, , France
Patients applied
Trial Officials
Nathalie MASSIN, MD
Principal Investigator
CHI Créteil
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials